Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
Open Label, Multicenter, Phase II Study of Patients With Treatment Naïve Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Randomized to Stereotactic Radiosurgery (SRS) and Osimertinib or Osimertinib Alone
Sponsor: AstraZeneca
Listed as NCT03769103, this PHASE2 trial focuses on Brain Metastases and Lung Cancer Non-small Cell Stage IV and remains ongoing. Sponsored by AstraZeneca, it has been updated 10 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
10 versions recorded-
Nov 2024 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Mar 2021 — Jul 2024 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Dec 2019 — Jan 2021 [monthly]
Recruiting PHASE2
-
Apr 2019 — Dec 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2019 — Apr 2019 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Not Yet Recruiting PHASE2
-
Jan 2019 — Feb 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- British Columbia Cancer Agency
- Princess Margaret Hospital, Canada
- Sunnybrook Health Sciences Centre
For direct contact, visit the study record on ClinicalTrials.gov .